Investigating a new way to reduce inflammation by targeting a specific protein in immune cells
Targeting SHP-1 through a newfound metabolite-regulated cysteine activation site
This study is exploring how a substance called itaconate can help reduce inflammation in the body by affecting a specific protein in immune cells, and it's looking for new treatments that could make a real difference for people dealing with inflammatory conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10935990 on NIH RePORTER |
What this research studies
This research focuses on a metabolite called itaconate, which plays a crucial role in controlling inflammation by modifying specific proteins in immune cells known as macrophages. The team has developed a novel mass spectrometry method to identify how itaconate affects a protein called SHP-1, which is important for regulating inflammatory responses. By creating a library of itaconate-like compounds, they aim to discover new treatments that can effectively reduce inflammation by targeting this protein. The research will involve various scientific techniques, including protein crystallography and medicinal chemistry, to enhance the effectiveness of these compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals suffering from chronic inflammatory conditions such as autoimmune diseases or other inflammatory disorders.
Not a fit: Patients with non-inflammatory conditions or those who do not respond to anti-inflammatory treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new anti-inflammatory treatments that improve the management of inflammatory diseases.
How similar studies have performed: Other research has shown promising results in targeting similar pathways for inflammation control, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Chouchani, Edward Thomas — Dana-Farber Cancer Inst
- Study coordinator: Chouchani, Edward Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.